Tag: option

Expansion highlights affordable rates, rapid approvals, and broader access for Ohio loan applicants

Compare the leading payday loan lenders in Seattle for 2025 and learn how borrowers with all credit backgrounds can access fast and secure short-term financing.

Public curiosity around nerve health is rising in 2025, with searches, podcasts, and social platforms highlighting natural approaches. Nerve Soothe enters this conversation with a formula designed around ingredient transparency, plant-based extracts, and consumer-driven expectations for wellness support.

Learn how Honest Loans connects US borrowers to quick $1,000 online loans with a simple application process and flexible options.

FUKUOKA, Japan, Aug. 15, 2025 (GLOBE NEWSWIRE) -- rYojbaba Co., Ltd. (Nasdaq: RYOJ) (“rYojbaba” or the “Company”), a Japanese labor consulting and health services company, today announced the closing of its initial public offering of 1,250,000 Japanese common shares at a public offering price of US$4.00 per share. The total gross proceeds from the offering, before deducting underwriting discounts and other offering expenses payable by rYojbaba, was US$5 million. rYojbaba’s Japanese common shares began trading on the Nasdaq Capital Market on August 14, 2025, under the ticker symbol “RYOJ”.

TORONTO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- European Residential Real Estate Investment Trust (TSX: ERE.UN, “ERES”) is pleased to announce that the trustees of ERES have declared the August 2025 monthly cash distribution of €0.005 per Unit and Class B LP Unit (the “August 2025 Distribution”), being equivalent to €0.06 per Unit annualized. The distribution will be payable to holders of the Units and Class B LP Units (the “Unitholders”) of record on August 29, 2025, with payment on September 15, 2025.

Hong Kong, Aug. 15, 2025 (GLOBE NEWSWIRE) -- BUUU Group Limited (Nasdaq: BUUU) (the “Company”), an established  meetings, incentives, conferences and exhibitions (“MICE”) solutions provider based in Hong Kong , today announced the closing of its initial public offering (the “Offering”) of 1,500,000 Class A ordinary shares (the “Class A Ordinary Shares”), at a price of $4.00 per Class A Ordinary Share (the “Offering Price”).

BOSTON, Aug. 15, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on August 12, 2025, the company issued inducement awards to Adam Craig, M.D., John Volpone and David Kirske under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”), consisting of (i) options to purchase an aggregate of 4,250,718 shares of X4’s common stock granted to Dr. Craig, (ii) options to purchase an aggregate of 4,250,718 shares of X4’s common stock granted to Mr. Volpone and (iii) options to purchase an aggregate of 2,833,812 shares of X4’s common stock granted to Mr. Kirske. In addition, effective on August 14, 2025, the company issued additional inducement awards to Dr. Craig, Mr. Volpone and Mr. Kirske under the 2019 Inducement Plan, consisting of (i) options to purchase an aggregate of 529,201 shares of X4’s common stock granted to Dr. Craig, (ii) options to purchase an aggregate of 529,201 shares of X4’s common stock granted to Mr. Volpone and (iii) options to purchase an aggregate of 352,800 shares of X4’s common stock granted to Mr. Kirske.

First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available small molecule with potential best-in-class profile